Ventruba P, Crha I, Müller P, Mlyncek M
I. gynek.-porod. klinika LF MU, Brno.
Ceska Gynekol. 1996 Feb;61(1):11-6.
To determine the safety and effectiveness of ZOLADEX depot (goserelin) in the therapy of endometriosis (study No. 9393CZ/0001).
A multicentric prospective open study of 60 women with endometriosis. R-AFS score of pelvic endomemtriosis was established in patients suffering from pelvalgia, dyspareunia and dysmenorrhoea during pre-treatment laparoscopy. The effect of Zoladex depot applied subcutaneously were evaluated by gynaecological and laboratory examinations, including assessment of subjective complaints every four weeks in the course of six months. Laparoscopic check-up was carried out immediately after terminating the therapy.
(1) The average total score of subjective complaints decreased by 90% after 24 weeks of treatment. (2) Treatment was successful in 67% patients, i.e. laparoscopic examination showed a decrease of the R-AFS score by at least 50%. In 28% treated women visible endometrial foci disappeared completely. (3) The most frequent side-effects of therapy are associated with hypoestrogenic effects of GnRH agonists. Vasomotor instability, flushes and night hyperidrosis occurred in 93% and 90% treated women, respectively.
Goserelin acetate is a synthetic GnRH agonist suitable for safe and effective therapy of pelvic endometriosis. The administration of 3.6 mg goserelin every day for 24 weeks reduced markedly the size of endomerial foci and painful symptoms.
确定诺雷德长效注射剂（戈舍瑞林）治疗子宫内膜异位症的安全性和有效性（研究编号9393CZ/0001）。
对60例子宫内膜异位症女性患者进行多中心前瞻性开放性研究。在治疗前腹腔镜检查时，对患有盆腔疼痛、性交困难和痛经的患者确定盆腔子宫内膜异位症的R-AFS评分。通过妇科和实验室检查评估皮下注射诺雷德长效注射剂的效果，包括在六个月的疗程中每四周评估主观症状。治疗结束后立即进行腹腔镜检查。
（1）治疗24周后，主观症状的平均总分下降了90%。（2）67%的患者治疗成功，即腹腔镜检查显示R-AFS评分降低至少50%。在28%接受治疗的女性中，可见的子宫内膜病灶完全消失。（3）治疗最常见的副作用与GnRH激动剂的低雌激素效应有关。血管运动不稳定、潮热和夜间多汗分别发生在93%和90%接受治疗的女性中。
醋酸戈舍瑞林是一种合成的GnRH激动剂，适用于盆腔子宫内膜异位症的安全有效治疗。每天注射3.6mg戈舍瑞林，持续24周，可显著减小子宫内膜病灶的大小并减轻疼痛症状。
